Nuclide internal irradiation treatment sensitizing medicine and preparation method thereof

Nuclear self-assembled in high GSH environment by using disulfide-linked block phenylalanine polypeptide fragments in nuclide-targeted therapy, combining peptide-drug conjugates targeting recognition units and nuclide units. Insufficient drug intake and short retention time in targeted treatment of steroids, the problem of insulin-targeted treatment has achieved more efficient tumor treatment effects and lower dose treatment effects.

CN118903483APending Publication Date: 2024-11-08XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411184635.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-27
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing nuclide-targeted treatments are poor in tumor treatment due to insufficient uptake, short retention time and insufficient killing efficacy in tumor cells, and nanomaterials are identified and removed in the body, affecting the treatment effect, and May trigger a biological response.

Method used

The peptide-drug conjugate formed by using block phenylalanine polypeptide fragments containing disulfide bonds as sensitization units, combining target recognition units and nuclide units, breaking the disulfide bonds under high GSH environment and self-assembly Form nanostructures to enhance therapeutic effects and prolong drug retention time.

Benefits of technology

It has achieved the effect of improving intratumor irradiation treatment at lower radioactive doses, reducing the toxic effects on non-target organs, prolonging the treatment cycle, and improving treatment efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903483A_ABST
    Figure CN118903483A_ABST
Patent Text Reader

Abstract

The invention provides a sensitizing medicine for nuclide internal irradiation treatment and a preparation method thereof, and relates to the technical field of biological imaging and treatment materials. The sensitizing drug for the irradiation therapy in the nuclide comprises a nuclide unit, a targeted recognition unit and a sensitizing unit. The nuclide unit comprises a metal chelating agent and a radioactive metal nuclide, and the radioactive metal nuclide is subjected to radioactive imaging or in-nuclide irradiation treatment. The sensibilization unit comprises a disulphide bond connected block phenylalanine polypeptide fragment, and the disulphide bond can consume a high glutathione level in a tumor, improve a microenvironment in a cell and enhance an internal irradiation treatment killing effect; the targeting recognition unit and the sensibilization unit are connected through a disulfide bond, so that the targeting recognition unit not only has a targeting effect, but also can hinder pi-pi superposition between benzene rings and prevent phenylalanine polypeptide from folding in an aqueous solution, so that the polypeptide is in a monomolecular dispersed state in vitro.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the technical field of biological imaging and therapeutic materials, and in particular to a radionuclide internal irradiation therapy sensitization drug and a preparation method thereof. Background Art

[0002] Treatments for malignant tumors are changing with each passing day. Precision tumor treatments represented by targeted therapy have attracted widespread attention because they can specifically identify tumors and reduce toxic side effects in non-target organs. Targeted radionuclide therapy (TRT) provides a new method for treating malignant tumors by using radionuclides to directly destroy tumor cells. Radioactive drug labeling 67 Cu, 64 Cu, 188 Re, 177 Lu, 90 Y. 223 Ra and 225 Ac and other therapeutic radionuclides use the β or α rays they emit to produce ionizing radiation effects, which directly have a fatal effect on tumor cells, and the side effects and crossfire effects of radioactive rays can also indirectly affect adjacent tumor cells. However, the insufficient tumor uptake, short retention time, and insufficient killing efficiency of therapeutic radioactive drugs limit their effective radiation dose, resulting in poor tumor treatment effects, which is the pain point and difficulty of clinical transformation.

[0003] Glutathione (GSH) is a small molecule antioxidant present in almost all animal cells. It is composed of three amino acids: glutamic acid, cysteine ​​and glycine. It plays a key role in maintaining intracellular redox balance, scavenging harmful free radicals (such as reactive oxygen species), and acting as an intracellular antioxidant. The concentration of glutathione in cells is very important for the health and function of cells, and changes in its levels are associated with a variety of disease states, including cancer and immune system disorders. The normal level of glutathione in human tissues ranges from 0.1mM to 10mM. The concentration of GSH in cancer cells is several times that of normal cells, and the intracellular GSH concentration (1-10mM) is about 1000 times higher than that in the extracellular compartment (2-20μM). In the tumor cell microenvironment, GSSG, as an oxidized form of GSH, is produced by two GSH molecules through sulfhydryl dehydrogenation. The redox state of the cell is highly correlated with changes in the GSH / GSSG ratio. When the GSH / GSSG ratio decreases, cells are transformed into an oxidized state, and their ability to scavenge free radicals such as ROS is weakened. During radiotherapy, tumor cells reduce the damage caused by ROS by increasing GSH levels, which reduces the therapeutic effect. Studies have shown that effective consumption of GSH can increase the ROS generated by radiotherapy, thereby further improving the efficiency of radiotherapy.

[0004] At the same time, dose limitation is the main limiting factor of internal irradiation therapy. In order to increase the effective local radiation dose of the tumor and improve the efficacy, a variety of nanomaterials have been developed as carriers of radionuclides, including organic polymers (such as liposomes, serum albumin, polydopamine), and inorganic nanocarriers (such as gold nanoparticles, magnetic nanoparticles, and silica nanoparticles). These nanomaterials use enhanced permeability and retention effects to effectively transport radionuclides to the tumor site through the gaps of the capillary endothelium. This process is called enhanced permeability and retention effect (EPR). And by modifying specific antibodies or ligands on the surface of nanomaterials, precise active targeting of tumor cells can be achieved, thereby efficiently delivering radionuclides. This radioactive internal irradiation radionuclide therapy based on nanomaterials has become an important direction of anti-cancer research. However, although the size characteristics of nanomaterials show unique advantages in many applications, they also bring a series of problems. Most nanomaterials are recognized and cleared by the mononuclear macrophage system in the body after entering the body. This mechanism significantly reduces their effective concentration at the target site, thereby affecting the effect of tumor treatment. In addition, the ingestion of nanomaterials may trigger various biological responses, such as activating the immune system, inducing cytotoxicity, or leading to long-term accumulation in body tissues, thus causing potential adverse effects on patients.

[0005] Compared with traditional nanomaterials, the molecular structure of responsive in situ self-assembly can be constructed according to the tumor microenvironment in vivo, which can maintain the small molecule form of polypeptide under normal physiological conditions in vivo. Structural changes will only occur in the acidic environment unique to tumors, the redox environment rich in peroxides or the specific enzyme environment, that is, the self-assembly process is initiated to form the corresponding nanostructure. This nanostructure can help drugs to be stably retained in the local tumor, prolong the treatment cycle, enhance the treatment effect, and reduce the toxic effects on non-target organs. The in vivo site-specific responsive self-assembly strategy has been widely used in drug delivery, tumor treatment, diagnostic imaging and other fields, providing a new strategy for molecular medicine. The hydrophilic peptide sequence with the ability to consume the high GSH level of the tumor and the intracellular self-assembly ability is covalently linked to the therapeutic nuclide. The constructed peptide-drug conjugate can specifically accumulate in the tumor site, achieve internal radiation therapy sensitization and local long-term drug retention effect, and effectively improve the internal radiation therapy effect of the tumor.

[0006] Based on the phenylalanine peptide containing SS bond as the sensitizing unit, we introduced the targeting group and the radionuclide unit at the specific site. On the one hand, the probe can consume GSH to break the disulfide bond only in the high GSH environment (the tumor cell has a high GSH environment), start self-assembly, and form nanomaterials. On the other hand, the introduction of the radionuclide unit can expand the innovative application of chelating a variety of radionuclides to realize the integrated diagnosis and treatment function of the probe. This strategy is expected to achieve better therapeutic effects while using lower radioactive doses. This trend may become the development direction of radionuclide internal irradiation therapy in the future. Summary of the invention

[0007] The purpose of the present application is to provide a radionuclide internal irradiation therapy sensitization drug and a preparation method thereof, aiming to solve the existing problems.

[0008] To achieve the above objectives, the present application provides a radionuclide internal irradiation therapy sensitizing drug, comprising a radionuclide unit, a targeting recognition unit and a sensitizing unit, wherein the sensitizing unit is a block phenylalanine polypeptide fragment connected by a disulfide bond.

[0009] In some embodiments, the molecular formula of the sensitizing unit is: HOOC-CH 2 -CH 2 -SS-CH 2 -CH 2 -CONH-Lys-Phe-Phe-Tyr-Gln-Gln-CONH 2 .

[0010] In some embodiments, the targeting recognition unit may be a polypeptide sequence RGD or PFPN, wherein the polypeptide sequence RGD is an RGD cyclic peptide, and PFPN is a molecule targeting melanin, having a structure shown in Formula I:

[0011]

[0012] The polypeptide sequence RGD is selected from any one of c(RGD)yk, c(RGD)fc, c(RGD)yc, and c(RGD)fk, the sequence of c(RGD)yk is cyclo(Arg-Gly-Asp-d-Tyr-Lys), the sequence of c(RGD)fc is cycl o(Arg-Gly-Asp-d-Phe-Cys), the sequence of c(RGD)yc is cyclo(Arg-Gly-Asp-D-Tyr-Cys), and the sequence of c(RGD)fk is cyclo(Arg-Gly-Asp-d-Phe-Lys).

[0013] In some embodiments, the nuclide unit includes a metal chelator and a radioactive metal nuclide, wherein the metal chelator can be selected from the bifunctional ligand p-SCN-Bn-DOTA or p-SCN-Bn-NOTA; the metal nuclide can be selected from 67 Cu, 64 Cu, 177 Lu, 68 Ga, 111 In, 89 Zr, 90 Y. 223 Ra, 225 Any one of Ac.

[0014] In some embodiments, the radionuclide internal irradiation therapy sensitization drug may have a structure shown in Formula II, Formula III or Formula IV:

[0015]

[0016]

[0017] Wherein, the targeting recognition unit of the radionuclide internal irradiation therapy sensitizing drug of the structure shown in formula II is c(RGD)yk, and the metal chelator of the radionuclide unit is p-SCN-Bn-DOTA; the targeting recognition unit of the radionuclide internal irradiation therapy sensitizing drug of the structure shown in formula III is c(RGD)yk, and the metal chelator of the radionuclide unit is p-SCN-Bn-NOTA; the targeting recognition unit of the radionuclide internal irradiation therapy sensitizing drug of the structure shown in formula IV is PFPN, and the metal chelator of the radionuclide unit is p-SCN-Bn-NOTA. The metal nuclide can be selected from 67 Cu, 64 Cu, 177 Lu, 68 Ga, 111 In, 89 Zr, 90 Y. 223 Ra, 225 Any of Ac, where 68 Ga, 111 In, 89 Zr can only be used for nuclear imaging.

[0018] For example, the nuclide 64 When Cu is used, the structural formula of the radionuclide internal irradiation therapeutic drug may be as shown in Formula V or Formula VI:

[0019]

[0020]

[0021] For example, the nuclide 177When Lu, the structural formula of the radionuclide internal irradiation therapeutic drug can be as shown in Formula VII:

[0022]

[0023] For example, the nuclide 68 When Ga, the structural formula of the radionuclide internal irradiation therapeutic drug can be as shown in Formula VIII or IX:

[0024]

[0025] In some embodiments, the nuclear internal radiation therapy drug can be used for tumor nuclear imaging and / or tumor nuclear internal radiation therapy.

[0026] In some embodiments, the imaging effective concentration of the radionuclide internal irradiation therapy drug is 0.5-1 nmol / g, and the therapeutic effective concentration is 5-10 nmol / g.

[0027] The present application also provides a method for preparing the above-mentioned radionuclide internal irradiation therapy sensitization drug, comprising:

[0028] The sensitization unit and the target recognition unit are synthesized through an amide condensation reaction to obtain a first intermediate;

[0029] synthesizing the second intermediate by reacting the first intermediate with a metal chelator through an amide condensation reaction;

[0030] The second intermediate is radioactively labeled with a radioactive metal nuclide to obtain the nuclide internal radiation therapy sensitization drug.

[0031] Compared with the prior art, the beneficial effects of this application include:

[0032] The radionuclide internal irradiation therapy sensitization drug provided by the present application includes a targeting recognition unit, a sensitization unit and a radionuclide unit. The sensitization unit is a block phenylalanine polypeptide fragment connected by a disulfide bond. The disulfide bond can consume the high glutathione level in the tumor, improve the intracellular microenvironment, and enhance the killing effect of internal irradiation therapy; the phenylalanine polypeptide contains multiple hydrophobic benzene ring structures, which can be β-folded to form supramolecular nano-micelles through π-π superposition and intermolecular hydrogen bonding, and can achieve a longer local effect on the tumor at a lower radioactive dose. The targeting recognition unit and the sensitization unit are connected by a disulfide bond, so that the targeting recognition unit not only has a targeting effect, but also can hinder the π-π superposition between the benzene rings, prevent the phenylalanine polypeptide from folding in the aqueous solution, and make the polypeptide in vitro into a single molecule dispersed state. The radionuclide unit can be connected to different metal nuclides for radionuclide imaging or radionuclide internal irradiation therapy. When the radionuclide internal irradiation therapy sensitization drug enters the tumor cell, the disulfide bond is disconnected to consume the high glutathione in the tumor cell, and self-assembly is initiated at the same time, respectively enhancing the killing effect of internal irradiation therapy and prolonging the action time. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] In order to more clearly illustrate the technical solutions of the embodiments of the present application, the drawings required for use in the embodiments will be briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present application and therefore should not be regarded as limiting the scope of the present application.

[0034] Figure 1 The mass spectrometry results of PEP1-c(RGD)yk prepared in Example 1;

[0035] Figure 2 The mass spectrometry result of DOTA-PEP1-c(RGD)yk prepared in Example 1;

[0036] Figure 3 Transmission electron microscopy imaging of DOTA-PEP1-c(RGD)yk prepared in Example 1 after co-incubation with GSH;

[0037] Figure 4 Determination of critical micelle concentration after co-incubation of DOTA-PEP1-c(RGD)yk prepared in Example 1 with GSH;

[0038] Figure 5 This is the particle size distribution diagram of DOTA-PEP1-c(RGD)yk prepared in Example 1 after incubation with GSH;

[0039] Figure 6 Zeta potential of DOTA-PEP1-c(RGD)yk prepared in Example 1 before and after incubation with GSH;

[0040] Figure 7The radionuclide internal irradiation therapy sensitization drug prepared in Example 1 64 Cu-DP1R radiolabeled purity;

[0041] Figure 8 Drugs to enhance sensitization for radionuclide internal irradiation therapy 64 Cu-DP1R uptake results in U87-MG cells;

[0042] Fig. 9 Drugs to enhance sensitization for radionuclide internal irradiation therapy 64 The result of the change of GSH / GSSG levels after Cu-DOTA-PEP1-c(RGD)yk and U87-MG cells were co-incubated for 24 hours;

[0043] Fig.10 Drugs to enhance sensitization for radionuclide internal irradiation therapy 64 The cell survival rate results after incubation of Cu-DP1R with U87MG cells;

[0044] Fig.11 Drugs to enhance sensitization for radionuclide internal irradiation therapy 64 Comparison of PET imaging results of Cu-DP1R in U87MG tumor-bearing mice and MCF7 tumor-bearing mice;

[0045] Fig.12 Drugs to enhance sensitization for radionuclide internal irradiation therapy 64 The results of the biodistribution analysis of Cu-DP1R in different organs of U87MG tumor-bearing mice and MCF7 tumor-bearing mice 72 hours after injection;

[0046] Fig.13 Drugs to enhance sensitization for radionuclide internal irradiation therapy 64 Quantitative analysis results of the average PET signal intensity of Cu-DP1R in the tumor of U87MG tumor-bearing mice during PET imaging;

[0047] Fig.14 Drugs to enhance sensitization for radionuclide internal irradiation therapy 64 Results of changes in tumor size when Cu-DP1R was used for treatment;

[0048] Fig.15 Drugs to enhance sensitization for radionuclide internal irradiation therapy 64 Survival curve of tumor-bearing mice when Cu-DP1R was used for treatment;

[0049] Fig.16 Drugs to enhance sensitization for radionuclide internal irradiation therapy 64 Results of liver and kidney function indicators of tumor-bearing mice when Cu-DP1R was used for treatment;

[0050] Fig.17 Drugs to enhance sensitization for radionuclide internal irradiation therapy 177Results of changes in tumor size when Lu-DP1R was used for treatment;

[0051] Fig.18 Drugs to enhance sensitization for radionuclide internal irradiation therapy 177 Survival curve of tumor-bearing mice when Lu-DP1R was used for treatment;

[0052] Fig.19 Prepared in Example 6 68 Application of Ga-DP1R in biological imaging;

[0053] Fig. 20 This is the mass spectrometry result of NP1R prepared in Example 7;

[0054] Fig.21 This is a graph showing the results of determining the critical micelle concentration after co-incubation of NP1R prepared in Example 7 with GSH;

[0055] Fig. 22 This is a transmission electron microscopy imaging result after the NP1R prepared in Example 7 was co-incubated with GSH;

[0056] Fig.23 Prepared in Example 8 64 PET imaging results of Cu-NP1R in U87MG tumor-bearing mice and MCF7 tumor-bearing mice;

[0057] Fig.24 Prepared in Example 8 64 The biodistribution results of Cu-NP1R in U87MG tumor-bearing mice and MCF7 tumor-bearing mice;

[0058] Fig.25 Prepared in Example 8 64 Quantitative analysis results of the average PET signal intensity of Cu-NP1R in U87MG tumors of U87MG tumor-bearing mice;

[0059] Fig.26 Prepared in Example 9 68 In vitro stability of Ga-NOTA-PEP1-PFPN labeling;

[0060] Fig. 27 Prepared in Example 9 68 PET imaging of Ga-NOTA-PEP1-PFPN in B16F10 tumor-bearing mice;

[0061] Fig.28 Prepared in Example 9 68 Quantitative analysis of the average PET signal intensity in B16F10 tumors of Ga-NOTA-PEP1-PFPN-bearing mice;

[0062] Fig.29Prepared in Comparative Example 1 64 Cu-DPR and prepared in Example 1 64 Comparison of PET imaging results of Cu-DP1R in U87MG tumor-bearing mice. DETAILED DESCRIPTION

[0063] Example 1

[0064] Example 1 provides a radionuclide internal irradiation therapy sensitization drug 64 Cu-DP1R, the target recognition unit is c(RG D)yk, and the precursor molecular formula of the sensitization unit is: HOOC-CH 2 -CH 2 -SS-CH 2 -CH 2 -CONH-Lys(Boc)-Phe-Phe-Tyr-Gln-Gln-CONH 2 (denoted as PEP1), the nuclides in the nuclide unit are 64 Cu, the metal chelator is p-SC N-Bn-DOTA. The reactants and reagents include 1-ethyl-3 (3-dimethylpropylamine) carbodiimide (EDCI), N-hydroxysuccinimide (NHS), N, N-diisopropylethylamine (DIPEA), c(RGD)yk, p-SCN-Bn-DOTA, 64 CuCl 2 .

[0065] 64 The specific steps of the preparation process of Cu-DP1R are:

[0066] (1) Synthesis of PEP1: The synthesis of the small molecule peptide PEP1 adopts the mature peptide solid phase synthesis technology. After the reaction is monitored by HPLC, a C18 semi-preparative HPLC column is used for separation and purification to obtain a PEP1 peptide with a purity of more than 95%.

[0067] (2) Synthesis of PEP1-c(RGD)yk: PEP1 (1 mmol), EDCI (2 mmol), NHS (1.2 mmol) and anhydrous DMSO (500 ul) were added to a 1.5 ml centrifuge tube respectively, and the mixture was reacted at room temperature for 4 h under magnetic stirring. Then c(RGD)yk (1.5 mmol) and DIPEA (20 mmol) were added to the mixture and reacted at room temperature for 10 h. PEP1-c(RGD)yk was purified by HPLC and separated and purified using a C18 semi-preparative HPLC column. The precipitate washed with acetonitrile was dried by rotary evaporation. 1 ml of anhydrous formaldehyde was added to the obtained solid product, and after it was fully dissolved, it was transferred to a 5 ml glass bottle and blown dry by a nitrogen blower to obtain the final product PEP1-c(RGD)yk (0.7 mmol). The mass spectrometry results of the synthesized PEP1-c(RGD)yk are shown in the figure. Figure 1 Shown: [M+H] + :[C 80 H 111 N 19 O 21 S 2 +H] + :m / z=1738.77161, found 1738.77108.

[0068] (3) Synthesis of DOTA-PEP1-c(RGD)yk: PEP1-c(RGD)yk was hydrolyzed with trifluoroacetic acid and dichloromethane in a volume ratio of 1:3 to remove tert-butyloxycarbonyl (t-Butyloxy carbonyl, Boc), and the reaction was carried out at room temperature for 4 hours and then suspended to dryness. The product after Boc removal (1 mmol) was dissolved in 500 μL anhydrous DMSO, and 2 mmol of p-SCN-Bn-DOTA and 10 mmol of DIPEA were added to react at room temperature for 6 hours. The final product DOTA-PEP1-c(RGD)yk (abbreviated as DP1R) was purified by HPLC and suspended to dryness by rotary evaporator to obtain solid dry powder. 1 ml of anhydrous formaldehyde was added to the obtained solid product, and after it was fully dissolved, it was transferred to a 5 ml glass bottle and dried by nitrogen blowing to obtain the final product DOTA-PEP1-c(RGD)yk (0.5 mmol). The structure of the final synthesized DOTA-PEP1-c(RGD)yk was identified by MALDI-TOF mass spectrometry, and the chemical purity was detected by HPLC. Figure 2 Shown: [M+2H] +2 :[C 99 H 136 N 24 O 27 S 3 +2H] +2:m / z=1095.46572, found1095.46491.

[0069] In a high GSH environment, the disulfide bonds in DOTA-PEP1-c(RGD)yk were broken and self-assembled. After co-incubation with GSH, micelle-like structures with an average diameter of about 27.55±6.43nm were observed under electron microscopy, as shown in Figure 2. Figure 3 shown.

[0070] As a hydrophobic probe, pyrene has five electronic vibration peaks in the fluorescence emission spectrum in the solution. The ratio of the intensity of the first and third vibration peaks I1 / I3 strongly depends on the polarity of the environment in which pyrene is located. The critical micelle concentration of the surfactant can be measured by the sudden change of the I1 / I3 value after pyrene is solubilized in micelles (micelle formation). By plotting the I1 / I3 ratio against the concentration, the critical micelle concentration value can be obtained by the tangent method. In the experiment of determining the self-assembly concentration of DOTA-PEP1-c(RGD)yk using pyrene, the critical micelle concentration of the radionuclide internal irradiation therapy sensitization drug was measured to be 13.962μM, such as Figure 4 shown.

[0071] The hydrated particle size of DOTA-PEP1-c(RGD)yk after co-incubation with GSH was 284.28±27.99nm. Figure 5 The zeta potential changed from 3.65±0.49 mV before co-incubation with GSH to -36.43±1.89 mV after co-incubation with GSH. Figure 6 shown.

[0072] (4) 64 The labeling steps of Cu-DP1R are as follows: 64 CuCl 2 The solution was adjusted to pH 5.0 with 0.1 M sodium acetate buffer solution, and the synthesized DP1R was added and reacted at 100°C for 30 minutes to obtain 64 Cu-DP1R. Take 10 μL of the product and use high performance liquid chromatography to analyze the radiochemical purity, using a C18 column at a flow rate of 1 mL / min. If the radiochemical purity is > 90%, subsequent experiments can be performed. 177 Lu-DP1R, 68 Ga-DP1R.

[0073] mark 64 Cu obtains radioactive product 64 Cu-DP1R, its labeling rate and radiochemical purity are both >95%, such as Figure 7 and has good in vitro stability.

[0074] Example 2

[0075] Example 2 provides a radionuclide internal irradiation therapy sensitization drug 64 Application of Cu-DP1R at the cellular level.

[0076] In an in vitro experiment, the response of U87MG tumor cells to free 64 CuCl 2 , 64 Cu-DR (without the sensitizing unit PEP1 compared to Example 1), 64 The different uptake of Cu-DP1R in the cell membrane and inside the cell at 4 hours. Figure 8 When cells are exposed to free 64 CuCl 2 During incubation, almost no cellular uptake was detected. Targeted radiopharmaceuticals mainly target integrin αvβ3 on the cell membrane and enter the cell through internalization to exert their effects. 64 90.98% of the radiopharmaceuticals taken up by the Cu-DP1R group were internalized into the cells to exert their effects, which was similar to the specific targeted radiopharmaceuticals 64 The results of Cu-DR were similar. 64 Cu-DP1R uptake ratio 64 The value in Cu-DR group was as high as 5 times (P<0.05).

[0077] In addition, this study found that the polypeptide molecule DP1R containing SS bonds can significantly consume GSH and improve the intracellular microenvironment through the reactivity of SS bonds with GSH ( Fig. 9 ). In radiotherapy, effective consumption of GSH can increase the ROS produced by radiotherapy, thereby further improving the efficiency of radiotherapy. In vitro treatment of U87MG cells revealed 64 The Cu-DP1R group showed a significant killing effect ( Fig.10 ).and, 64 Cu-DP1R showed better performance at a dose of 0.1MBq than that at 0.2MBq. 64 Cu-DR has the ability to kill tumor cells. This suggests that the self-assembly strategy is expected to achieve better therapeutic effects at a lower radioactive dose.

[0078] Example 3

[0079] Example 3 provides a radionuclide internal irradiation therapy sensitization drug 64 Application of Cu-DP1R in biological imaging, the specific steps are as follows:

[0080] Animal tumor model construction: BALB / C-nu / nu nude mice (female, 3-4 weeks old) were provided by Beijing Huafukang Biotechnology Co., Ltd. and were raised in the animal experiment center of Huazhong University of Science and Technology in a special pathogen-free barrier system. All animals used in the experiment were reviewed by the Experimental Animal Use and Management Committee of Tongji Medical College of Huazhong University of Science and Technology. U87 glioma cells 2×10 5 Each cell was suspended in 150ul PBS and implanted subcutaneously in the axilla of the right upper limb of nude mice. When the tumor diameter reached 0.3-0.5cm, it could be used for animal experimental research.

[0081] Tumor-bearing mice (n=4) were first injected into the tail vein 64 Cu-DP1R, and PET imaging was performed at 1, 4, 24, and 72 hours. 64 Cu-DR. in low expression of integrin α v β 3 No obvious tumor uptake was observed in the MCF-7 subcutaneous tumor model. Fig.11 ). 64 The high uptake of Cu-DP1R group tumors lasted until 72 hours. 64 The signal of tumor uptake in the Cu-DR group was significantly weakened at 72 hours. Fig.12 )Show injection 64 Cu-DP1R uptake in U87MG tumor-bearing mice was significantly higher after 72 h 64 Cu-DR group. Injection 64 The tumor uptake of Cu-DP1R in U87MG tumor-bearing mice was also significantly higher than that in injected 64 Cu-DP1R in MCF-7 tumor-bearing mice. 64 Cu-DP1R is metabolized rapidly in various important organs. 64 Cu-DR, 64 Region of interest (ROI) of Cu-DP1R in PET images of U87MG tumor-bearing mice at different time points ( Fig.13 ),Discover 64 Cu-DP1R tumor uptake was significantly higher than 64 Cu-DR uptake in tumor lesions. And up to 72 hours 64 Cu-DP1R 64 Compared with the Cu-DR group, there was still obvious tumor uptake.

[0082] The above description 64 Cu-DP1R can self-assemble in tumor tissue and prolong the duration of tumor imaging.

[0083] Example 4

[0084] Example 4 provides a radionuclide internal irradiation therapy sensitization drug 64 The application of Cu-DP1R in biotherapy, the specific steps are as follows:

[0085] Animal tumor model construction: BALB / C-nu / nu nude mice (female, 3-4 weeks old) were provided by Beijing Huafukang Biotechnology Co., Ltd. and were raised in the animal experiment center of Huazhong University of Science and Technology in a special pathogen-free barrier system. All animals used in the experiment were reviewed by the Experimental Animal Use and Management Committee of Tongji Medical College of Huazhong University of Science and Technology. U87 glioma cells 2×10 5 Each cell was suspended in 150ul PBS and implanted subcutaneously in the axilla of the right upper limb of nude mice. When the tumor diameter reached 0.3-0.5cm, it could be used for animal treatment experimental research.

[0086] The tumor-bearing mice were divided into 4 groups, namely PBS (injected with equal volume of PBS), free 64 Cu (injection dose 66.6MBq), 64 Cu-DR (injection dose 66.6MBq), 64 Cu-DP1R (injection dose of 66.6MBq) group, 5 mice in each group. The mice were closely observed, the tumor size and mouse weight were measured with a vernier caliper, the tumor volume was calculated, and the tumor growth and mouse survival rate curves were drawn. Tumor growth curve ( Fig.14 ) and mouse survival curve ( Fig.15 )show, 64 Cu-DP1R can significantly delay the growth of tumor tissue, and its therapeutic effect is better than that of the control group. At the end of the treatment observation period, blood samples of tumor-bearing mice in each treatment group were collected to measure serum liver function indicators including ALT, AST, ALP and renal function indicator BUN to evaluate liver and kidney function ( Fig.16 ). The results showed that there was no statistical difference in liver and kidney function among the treatment groups, and the ALT, AST, ALP, and BUN values ​​were above the normal range. 64 Cu-DP1R self-assembles in tumor tissue, which can prolong the retention time of the probe in the tumor, enhance the tumor treatment effect and have biocompatibility.

[0087] Example 5

[0088] Example 5 provides a radionuclide internal irradiation therapy sensitization drug 177 The application of Lu-DP1R in biotherapy, the specific steps are as follows:

[0089] Animal tumor model construction: BALB / C-nu / nu nude mice (female, 3-4 weeks old) were provided by Beijing Huafukang Biotechnology Co., Ltd. and were raised in the animal experiment center of Huazhong University of Science and Technology in a special pathogen-free barrier system. All animals used in the experiment were reviewed by the Experimental Animal Use and Management Committee of Tongji Medical College of Huazhong University of Science and Technology. U87 glioma cells 2×10 5 Each cell was suspended in 150ul PBS and implanted subcutaneously in the axilla of the right upper limb of nude mice. When the tumor diameter reached 0.3-0.5cm, it could be used for animal treatment experimental research.

[0090] The tumor-bearing mice were divided into 4 groups, namely PBS (injected with equal volume of PBS), free 177 Lu (injection dose 29.6MBq), 177 Lu-DR (injection dose 29.6MBq), 177 Lu-DP1R (injection dose of 29.6MBq) group, 50nmol, 5 mice in each group. The mice were closely observed, the tumor size and mouse weight were measured with a vernier caliper, the tumor volume was calculated, and the tumor growth and mouse survival rate curves were drawn. Tumor growth curve ( Fig.17 ) and mouse survival curve ( Fig.18 )show, 177 Lu-DP1R can significantly delay the growth of tumor tissue, and its therapeutic effect is better than that of the control group.

[0091] Example 6

[0092] Example 6 provides a radionuclide imaging drug 68 The application of Ga-DP1R in biological imaging, the specific steps are as follows:

[0093] Animal tumor model construction: BALB / C-nu / nu nude mice (female, 3-4 weeks old) were provided by Beijing Huafukang Biotechnology Co., Ltd. and were raised in the animal experiment center of Huazhong University of Science and Technology in a special pathogen-free barrier system. All animals used in the experiment were reviewed by the Experimental Animal Use and Management Committee of Tongji Medical College of Huazhong University of Science and Technology. U87 glioma cells 2×10 5 Each cell was suspended in 150ul PBS and implanted subcutaneously in the axilla of the right upper limb of nude mice. When the tumor diameter reached 0.3-0.5cm, it could be used for animal experimental research.

[0094] Tumor-bearing mice (n=4) were first injected into the tail vein 68 Ga-DP1R, PET imaging was performed at 0.5, 1, 2, and 4 hours ( Fig.19 ). 68 The uptake of the tumor in the Ga-DP1R group showed an increasing trend.

[0095] Example 7

[0096] Example 7 provides a multi-nuclide internal irradiation therapy sensitization drug 64 Cu-NOTA-PEP1-c(RGD)yk( 64 Cu-NP1R), the target recognition unit is c(RGD)yk, and the precursor molecular formula of the sensitization unit is: HOOC-CH 2 -CH 2 -SS-CH 2 -CH 2 -CONH-Lys(Boc)-Phe-Phe-Tyr-Gln-Gln-CONH 2 (denoted as PEP1), the metal nuclide is selected as 64 Cu, the metal chelator is p-SCN-Bn-NOTA, and the specific steps of the preparation method are similar to those of Example 1.

[0097] The mass spectrometry results of the synthesized NOTA-PEP1-c(RGD)yk (abbreviated as NP1R) are as follows [M+2H] +2 :[C 99 H 136 N 24 O 27 S 3 +2H] +2 :m / z=1095.46572,found 1095.46491( Fig. 20 ). The critical micelle concentration of NP1R is 15.992 μM ( Fig.21 ). After incubation with GSH, micelle structures with an average diameter of about 27.83±8.03nm were observed in TEM ( Fig. 22 ). After co-incubation with GSH, the disulfide bonds were broken, and the micelle diameter measured by DLS was 220.80±9.04nm and the Zeta potential was -41.02±3.27mV.

[0098] Example 8

[0099] Example 8 provides a multi-nuclide internal irradiation therapy sensitization drug 64 The application of Cu-NP1R in biological imaging, the specific steps are as follows:

[0100] Animal tumor model construction: BALB / C-nu / nu nude mice (female, 3-4 weeks old) were provided by Beijing Huafukang Biotechnology Co., Ltd. and were raised in the animal experiment center of Huazhong University of Science and Technology in a special pathogen-free barrier system. All animals used in the experiment were reviewed by the Experimental Animal Use and Management Committee of Tongji Medical College of Huazhong University of Science and Technology. U87 glioma cells 2×10 5Each cell was suspended in 150ul PBS and implanted subcutaneously in the axilla of the right upper limb of nude mice. When the tumor diameter reached 0.3-0.5cm, it could be used for animal experimental research.

[0101] Tumor-bearing mice (n=4) were first injected into the tail vein 64 Cu-NP1R, and PET imaging was performed at 1, 4, 24, and 72 hours. 64 Cu-NR. In the subcutaneous tumor model of MCF-7 cell line with low expression of integrin αvβ3, no obvious tumor uptake was observed ( Fig.23 ). 64 The high uptake of Cu-NP1R group tumors lasted until 72 hours. 64 The signal of tumor uptake in the Cu-NR group was significantly weakened at 72 hours. Fig.24 )Show injection 64 Cu-NP1R uptake in U87MG tumor-bearing mice was significantly higher after 72 h than 64 Cu-NR group. Injection 64 The tumor uptake of Cu-NP1R in U87MG tumor-bearing mice was also significantly higher than that in injected 64 Cu-NP1R in MCF-7 tumor-bearing mice. 64 Cu-NP1R is metabolized rapidly in various important organs. 64 Cu-NR, 64 Region of interest (ROI) of Cu-NP1R in PET images of U87MG tumor-bearing mice at different time points ( Fig.25 ),Discover 64 Cu-NP1R tumor uptake was significantly higher than 64 Cu-NR uptake in tumor lesions. And up to 72 hours 64 Cu-NP1R 64 There was still obvious tumor uptake compared with the Cu-NR group.

[0102] The above description 64 Cu-NP1R can self-assemble in tumor tissue and prolong the duration of tumor imaging.

[0103] Example 9

[0104] Example 9 provides a radionuclide imaging drug 68 Ga-NOTA-PEP1-PFPN, the target recognition unit is PFPN, and the precursor molecular formula of the sensitization unit is: HOOC-CH 2 -CH 2 -SS-CH 2 -CH 2-CONH-Lys(Boc)-Phe-Phe-Tyr-Gln-Gln-CONH 2 (denoted as PEP1), the nuclides in the nuclide unit are 68 Ga, the metal chelator is p-SCN-Bn-NOTA, and its preparation method is similar to that of Example 1.

[0105] NOTA-PEP1-PFPN was successfully synthesized and labeled 68 The reaction product obtained by Ga has a labeling rate and radiochemical purity of >95% and has good in vitro stability ( Fig.26 ).

[0106] Animal tumor model construction: C57 mice (female, 3-4 weeks old) were provided by Beijing Huafukang Biotechnology Co., Ltd. and were raised in the animal experiment center of Huazhong University of Science and Technology without a special pathogen barrier system. All animals used in the experiment were reviewed by the Experimental Animal Use and Management Committee of Tongji Medical College of Huazhong University of Science and Technology. B16F10 glioma cells 2×10 5 Each cell was suspended in 150ul PBS and implanted subcutaneously in the axilla of the right upper limb of the mouse. When the tumor diameter reached 0.3-0.5cm, it could be used for animal experimental research.

[0107] Tumor-bearing mice (n=4) were first injected into the tail vein 68 Ga-NOTA-PEP1-PFPN, and PET imaging was performed at 0.5, 1, and 2 hours. 68 Ga-NOTA-PFPN( Fig. 27 ). 68 Tumor uptake of Ga-NOTA-PEP1-PFPN was observed. 68 Ga-NOTA-PEP1-PFPN and 68 Compared with Ga-NOTA-PFPN, the uptake and outflow in the tumor lesion area is slower ( Fig.28 ).

[0108] The above description 68 Ga-NOTA-PEP1-PFPN can self-assemble in tumor tissue and prolong the duration of tumor imaging effect.

[0109] Comparative Example 1

[0110] Radionuclide internal irradiation therapy sensitization drug provided in comparative example 1 64 Cu-DPR, which is different from Example 1, has the molecular formula of the sensitizing unit as follows: HOOC-CH 2 -CH 2 -SS-CH 2 -CH 2-CONH-Phe-Phe-Tyr-Lys-CONH 2 (denoted as PEP), the rest of the structure and preparation method are the same as those in Example 1 and will not be repeated here.

[0111] Radionuclide internal irradiation therapy sensitization drug prepared in comparative example 1 64 Cu-DPR and radionuclide internal irradiation therapy sensitization drug prepared in Example 1 64 PET imaging of Cu-DP1R in U87MG tumor-bearing mice Fig.29 As shown in the figure, it can be seen that the radionuclide internal irradiation therapy sensitizing drug further synthesized by the sensitizing unit PEP1 of Example 1 has a lower liver background and a higher tumor uptake than the radionuclide internal irradiation therapy sensitizing drug synthesized by the sensitizing unit PEP of Comparative Example 1.

[0112] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present application, rather than to limit it. Although the present application has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present application.

[0113] In addition, those skilled in the art will appreciate that, although some embodiments herein include certain features included in other embodiments but not other features, the combination of features of different embodiments is meant to be within the scope of the present application and form different embodiments. For example, in the above claims, any one of the claimed embodiments may be used in any combination. The information disclosed in this background technology section is intended only to deepen the understanding of the overall background technology of the present application and should not be regarded as an admission or in any form of implication that the information constitutes prior art known to those skilled in the art.

Claims

1. A radionuclide internal irradiation therapy sensitization drug, characterized in that: It comprises a nuclide unit, a targeting recognition unit and a sensitizing unit, wherein the sensitizing unit is a block phenylalanine polypeptide fragment connected by a disulfide bond.

2. The radionuclide internal radiation therapy sensitization drug according to claim 1, characterized in that: The molecular formula of the sensitizing unit is: HOOC-CH2-CH2-SS-CH2-CH2-CONH-Lys-Phe-Phe-Tyr-Gln-Gln-CONH2.

3. The radionuclide internal radiation therapy sensitization drug according to claim 1, characterized in that: The targeting recognition unit can be selected from the polypeptide sequence RGD or PFPN; the polypeptide sequence RGD is selected from any one of c(RGD)yk, c(RGD)fc, c(RGD)yc, and c(RGD)fk; The PFPN has a structure shown in Formula I:

4. The radionuclide internal irradiation therapy drug according to claim 1, characterized in that: The nuclide unit comprises a metal chelator and a radioactive metal nuclide, wherein the metal chelator can be selected from the bifunctional ligand p-SCN-Bn-DOTA or p-SCN-Bn-NOTA; the metal nuclide can be selected from 67 Cu, 64 Cu, 177 Lu, 68 Ga, 111 In, 89 Zr, 90 Y. 223 Ra, 225 Any of Ac.

5. The radionuclide internal irradiation therapy sensitization drug according to claim 1, characterized in that: The radionuclide internal irradiation therapy sensitization drug may have a structure shown in Formula II, Formula III or Formula IV:

6. Use of the radionuclide internal irradiation therapeutic drug according to any one of claims 1 to 5, characterized in that: The radionuclide internal irradiation therapeutic drug can be used for tumor radionuclide imaging and / or tumor radionuclide internal irradiation therapy.

7. The use of the radionuclide internal irradiation therapeutic drug according to claim 6, characterized in that: The imaging effective concentration of the radionuclide internal irradiation therapeutic drug is 0.5-1 nmol / g, and the therapeutic effective concentration is 5-10 nmol / g.

8. A method for preparing a radionuclide internal radiation therapy sensitizing drug according to any one of claims 1 to 5, characterized in that: include: The sensitization unit and the target recognition unit are synthesized through an amide condensation reaction to obtain a first intermediate; synthesizing the second intermediate by reacting the first intermediate with a metal chelator through an amide condensation reaction; The second intermediate is radioactively labeled with a radioactive metal nuclide to obtain the nuclide internal radiation therapy sensitization drug.